Monoclonal antibodies for cancer immunotherapy

The Lancet

Volumn 373, Issue 9668, 2009, Pages 1033-1040

  Weiner, Louis M ^a   Dhodapkar, Madhav V ^b,c   Ferrone, Soldano ^d  

^a GEORGETOWN UNIVERSITY   (United States)

^b YALE UNIVERSITY   (United States)

^c ROCKEFELLER UNIVERSITY   (United States)

^d UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BEVACIZUMAB; FC RECEPTOR; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; MONOCLONAL ANTIBODY; RITUXIMAB; TOSITUMOMAB; TOSITUMOMAB I 131; TRASTUZUMAB; TUMOR ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN PRESENTATION; BREAST CANCER; CANCER IMMUNOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; CROSS PRESENTATION; CYTOTOXICITY; HUMAN; IMMUNE RESPONSE; LUNG CANCER; LYMPHOMA; PRIORITY JOURNAL; REVIEW;

EID: 62349132009     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)60251-8     Document Type: Review

References (93)

1. McLaughlin P., Grillo-Lopez A.J., Link B.K., et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16 (1998) 2825-2833
2. Kaminski M.S., Estes J., Zasadny K.R., et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 96 (2000) 1259-1266
3. Coiffier B. Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma. Semin Oncol 29 2 suppl 6 (2002) 18-22
4. Witzig T.E., Gordon L.I., Cabanillas F., et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20 (2003) 2453-2463
5. Sievers E.L., Appelbaum F.R., Spielberger R.T., et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood 93 (1999) 3678-3684
6. Kreitman R.J., Wilson W.H., Bergeron K., et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med 345 (2001) 241-247
7. Cobleigh M.A., Vogel C.L., Tripathy D., et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17 (1999) 2639-2648
8. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 (2001) 783-792
9. Vogel C.L., Cobleigh M.A., Tripathy D., et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20 (2002) 719-726
10. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353 (2005) 1673-1684
11. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
12. Miller R.A., Maloney D.G., Warnke R., et al. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med 306 (1982) 517-522
13. Leonard J.P., and Link B.K. Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab). Semin Oncol 29 1 suppl 2 (2002) 81-86
14. Lundin J., Kimby E., Bjorkholm M., et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 100 (2002) 768-773
15. Weiner L.M., Belldegrun A.S., Crawford J., et al. Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies. Clin Cancer Res 14 (2008) 502-508
16. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351 (2004) 337-345
17. Oegen J.G., Kuhns M.S., and Allison J.P. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 3 (2002) 611-618
18. Phan G.Q., Yang J.C., Sherry R.M., et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 100 (2003) 8372-8377
19. Steplewski Z., Lubeck M.D., and Koprowski H. Human macrophages armed with murine immunoglobulin G2a antibodies to tumors destroy human cancer cells. Science 221 (1983) 865-867
20. Heijnen I.A., and van de Winkel J.G. Human IgG Fc receptors. Int Rev Immunol 16 (1997) 29-55
21. Sulica A., Morel P., Metes D., et al. Ig-binding receptors on human NK cells as effecter and regulatory surface molecules. Int Rev Immunol 20 (2001) 371-414
22. Ravetch J.V., and Bolland S. IgG Fc receptors. Annu Rev Immunol 19 (2001) 275-290
23. Clynes R.A., Towers T.L., Presta L.G., et al. Inhibitory Fc receptors modulate in vivo cytoxicity against tumour targets. Nat Med 6 (2000) 443-446
24. Cartron G., Dacheux L., Salles G., et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99 (2002) 754-758
25. Weng W.K., and Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21 (2003) 3940-3947
26. Umana P., Jean-Mairet J., Moudry R., et al. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotechnol 17 (1999) 176-180
27. Ghetie V., and Ward E.S. Multiple roles for the major histocompatibility complex class I-related receptor FcRn. Annu Rev Immunol 18 (2000) 739-766
28. Shields R.L., Namenuk A.K., Hong K., et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 276 (2001) 6591-6604
29. Clark J.I., Alpaugh R.K., von Mehren M., et al. Induction of multiple anti-c-erbB-2 specificities accompanies a classical idiotypic cascade following 2B1 bispecific monoclonal antibody treatment. Cancer Immunol Immunother 44 (1997) 265-272
30. Heath W.R., and Carbone F.R. Cross-presentation, dendritic cells, tolerance and immunity. Annu Rev Immunol 19 (2001) 47-64
31. Amigorena S. Fc gamma receptors and cross-presentation in dendritic cells. J Exp Med 195 (2002) F1-F3
32. Dhodapkar K.M., and Dhodapkar M.V. Recruiting dendritic cells to improve antibody therapy of cancer. Proc Natl Acad Sci USA 102 (2005) 6243-6264
33. Dhodapkar M.V., Dhodapkar K.M., and Palucka A.K. Interactions of tumor cells with dendritic cells: balancing immunity and tolerance. Cell Death Differ 15 (2008) 39-50
34. Chamuleau M.E., Souwer Y., Van Ham S.M., et al. Class II-associated invariant chain peptide expression on myeloid leukemic blasts predicts poor clinical outcome. Cancer Res 64 (2004) 5546-5550
35. den Haan J.M., and Bevan M.J. Constitutive versus activation dependent cross presentation of immune complexes by CD8+ and CD8- dendritic cells in vivo. J Exp Med 196 (2002) 817-827
36. Dhodapkar K.M., Krasovsky J., Williamson B., et al. Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J Exp Med 195 (2002) 125-133
37. Nagata Y., Ono S., Matsuo M., et al. Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations. Proc Natl Acad Sci USA 99 (2002) 10629-10634
38. Rafiq K., Bergtold A., and Clynes R. Immune complex-mediated antigen presentation induces tumor immunity. J Clin Invest 110 (2002) 71-79
39. Schuurhuis D.H., Ioan-Facsinay A., Nagelkerken B., et al. Antigen-antibody immune complexes empower dendritic cells to efficiently prime specific CD8+ CTL responses in vivo. J Immunol 168 (2002) 2240-2246
40. Selenko N., Majdic O., Jager U., et al. Cross-priming of cytotoxic T cells promoted by apoptosis-inducing tumor cell reactive antibodies?. J Clin Immunol 22 (2002) 124-130
41. Akiyama K., Ebihara S., Yada A., et al. Targeting apoptotic tumor cells to FcR provides efficient and versatile vaccination against tumors by dendritic cells. J Immunol 170 (2003) 1641-1648
42. Groh V., Li Y.Q., Cioca D., et al. Efficient cross-priming of tumor antigen specific T cells by dendritic cells sensitized with diverse anti-MICA opsonized tumour cells. Proc Natl Acad Sci USA 102 (2005) 6461-6466
43. Sedlik C., Orbach D., Veron P., et al. A critical role for Syk protein tyrosine kinase in Fc receptor-mediated antigen presentation and induction of dendritic cell maturation. J Immunol 170 (2003) 846-852
44. Rodriguez A., Regnault A., Kleijmeer M., et al. Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat Cell Biol 1 (1999) 362-368
45. Banerjee D., Matthews P., Matayeva E., et al. Enhanced T cell responses to glioma cells coated with anti-EGF receptor antibody and targeted to activating FcgRs on human dendritic cells. J Immunotherapy 31 (2008) 113-120
46. Dhodapkar K.M., Banerjee D., Connolly J., et al. Selective blockade of the inhibitory Fc(gamma) receptor (Fc(gamma)RIIB) in human dendritic cells and monocytes induces a type I interferon response program. J Exp Med 204 (2007) 1359-1369
47. Franki S.N., Steward K.K., Betting D.J., et al. Dendritic cells loaded with apoptotic antibody-coated tumor cells provide protective immunity against B-cell lymphoma in vivo. Blood 111 (2008) 1504-1511
48. Jinushi M., Hodi F.S., and Dranoff G. Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity. Proc Natl Acad Sci USA 103 (2006) 9190-9195
49. de Bono J.S., Rha S.Y., Stephenson J., et al. Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity. Ann Oncol 15 (2004) 1825-1833
50. Taylor C., Hershman D., Shah N., et al. Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clin Cancer Res 13 (2007) 5133-5143
51. Weng W.K. Immune mediated antitumor effects with antibody therapy. ASCO Annual Meeting Educational Book (2005), ASCO, Chicago 200-204
52. Davis T.A., Grillo-Lopez A.J., White C.A., et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 18 (2000) 3135-3143
53. Davis T.A., Czerwinski D.K., and Levy R. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin Cancer Res 5 (1999) 611-615
54. Mellman I., and Steinman R.M. Dendritic cells: specialized and regulated antigen processing machines. Cell 106 (2001) 255-258
55. Amigorena S., and Bonnerot C. Fc receptors for IgG and antigen presentation on MHC class I and class II molecules. Semin Immunol 11 (1999) 385-390
56. Bave U., Magnusson M., Eloranta M.L., et al. Fc gamma RIIa is expressed on natural IFN-alpha-producing cells (plasmacytoid dendritic cells) and is required for the IFN-alpha production induced by apoptotic cells combined with lupus IgG. J Immunol 171 (2003) 3296-3302
57. Means T.K., Latz E., Hayashi F., et al. Human lupus autoantibody-DNA complexes activate dendritic cells through cooperation of CD32 and TLR9. J Clin Invest 115 (2005) 407-417
58. Regnault A., Lankar D., Lacabanne V., et al. Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J Exp Med 189 (1999) 371-380
59. Kalergis A.M., and Ravetch J.V. Inducing tumor immunity through the selective engagement of activating Fc receptors on dendritic cells. J Exp Med 195 (2002) 1653-1659
60. Bergtold A., Desai D.D., Gavhane A., et al. Cell surface recycling of internalized antigen permits dendritic cell priming of B cells. Immunity 23 (2005) 503-514
61. Boruchov A.M., Heller G., Veri M.C., et al. Activating and inhibitory IgG Fc receptors on human dendritic cells mediate opposing functions. J Clin Invest 115 (2005) 2914-2923
62. Kaneko Y., Nimmerjahn F., and Ravetch J.V. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313 (2006) 670-673
63. Dhodapkar K.M., Kaufman J.L., Ehlers M., et al. Selective blockade of inhibitory Fc{gamma} receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells. Proc Natl Acad Sci USA 102 (2005) 2910-2915
64. Nimmerjahn F., and Ravetch J.V. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 310 (2005) 1510-1512
65. Shahied L.S., Tang Y., and Alpaugh R.K. Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format. J Biol Chem 279 (2004) 53907-53914
66. Fischer N., and Leger O. Bispecific antibodies: molecules that enable novel therapeutic strategies. Pathobiology 74 (2007) 3-14
67. Jerne N.K. Towards a network theory of the immune system. Ann Immunol 125C (1974) 373-389
68. Spendlove L., Li L., Potter V., et al. A therapeutic human anti-idiotypic antibody mimics CD55 in three distinct regions. Eur J Immunol 30 (2000) 2944-2953
69. Chatterjee S.K., Tripathi P.K., Chakraborty M., et al. Molecular mimicry of carcinoembryonic antigen by peptides derived from the structure of an anti-idiotype antibody. Cancer Res 58 (1998) 1217-1224
70. Chang C.C., Hernandez-Guzman F.G., Luo W., Wang X., Ferrone S., and Ghosh D. Structural basis of antigen mimicry in a clinically relevant melanoma antigen system. J Biol Chem 280 (2005) 41546-41552
71. Koprowski H., Herlyn D., Lubeck M., et al. Human anti-idiotype antibodies in cancer patients: is the modulation of the immune response beneficial for the patient?. Proc Natl Acad Sci USA 81 (1984) 216-219
72. Steinitz M., Tamir S., Frodin J.E., et al. Human monoclonal anti-idiotypic antibodies. I. Establishment of immortalized cell lines from a tumor patient treated with mouse monoclonal antibodies. J Immunol 141 (1988) 3516-3522
73. Austin E.B., Robins R.A., Durrant L.G., et al. Human monoclonal anti-idiotypic antibody to the tumour-associated antibody 791T/36. Immunology 67 (1989) 525-530
74. Wettendorff M., Iliopoulos D., Tempero M., et al. Idiotypic cascades in cancer patients treated with monoclonal antibody CO17-1A. Proc Natl Acad Sci USA 86 (1989) 3787-3791
75. Losman M.J., Hansen H.J., Sharkey R.M., et al. Human response against NP-4, a mouse antibody to carcinoembryonic antigen: human anti-idiotype antibodies mimic an epitope on the tumor antigen. Proc Natl Acad Sci USA 88 (1991) 3421-3425
76. Saleh M.N., Stapleton J.D., Khazaeli M.B., and LoBuglio A.F. Generation of a human anti-idiotypic antibody that mimics the GD2 antigen. J Immunol 151 (1993) 3390-3398
77. Cheung N.K., Cheung I.Y., Canete A., et al. Antibody response to murine anti-GD2 monoclonal antibodies: correlation with patient survival. Cancer Res 54 (1994) 2228-2233
78. Fagerberg J., Steinitz M., Wigzell H., et al. Human anti- idiotypic antibodies induced a humoral and cellular immune response against a colorectal carcinoma-associated antigen in patients. Proc Natl Acad Sci USA 92 (1995) 4773-4777
79. Schultes B.C., Baum R.P., Niesen A., et al. Anti-idiotypeinduction therapy: anti-CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1). Cancer Immunol Immunother 46 (1998) 201-212
80. Cheung N.K., Guo H.F., Heller G., et al. Induction of Ab3 and Ab3′ antibody was associated with long-term survival after anti-G(D2) antibody therapy of stage 4 neuroblastoma. Clin Cancer Res 6 (2000) 2653-2660
81. Bradt B.M., DeNardo S.J., Mirick G.R., et al. Documentation of idiotypic cascade after Lym-1 radioimmunotherapy in a patient with non-Hodgkin's lymphoma: basis for extended survival?. Clin Cancer Res 9 suppl (2003) 4007-4012
82. Robins R.A., Denton G.W., Hardcastle J.D., et al. Antitumor immune response and interleukin 2 production induced in colorectal cancer patients by immunization with human monoclonal anti-idiotypic antibody. Cancer Res 51 (1991) 5425-5429
83. Fagerberg J., Frodin J.E., Wigzell H., et al. Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1). I. May induction of ab1-reactive T cells and anti-anti-idiotypic antibodies (ab3) lead to tumor regression after mAb therapy?. Cancer Immunol Immunother 37 (1993) 264-270
84. Fagerberg J., Hjelm A.L., Ragnhammar P., et al. Tumor regression in monoclonal antibody-treated patients correlates with the presence of anti-idiotype-reactive T lymphocytes. Cancer Res 55 (1995) 1824-1827
85. Mittelman A., Chen Z.J., Yang H., et al. Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma. Proc Natl Acad Sci USA 89 (1992) 466-470
86. Yao T.J., Meyers M., Livingston P.O., et al. Immunization of melanoma patients with BEC2-keyhole limpet hemocyanin plus BCG intradermally followed by intravenous booster immunizations with BEC2 to induce anti-GD3 ganglioside antibodies. Clin Cancer Res 5 (1999) 77-81
87. Foon K.A., Chakraborty M., John W.J., et al. Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotype antibody vaccine. J Clin Invest 96 (1995) 334-342
88. Foon K.A., Sen G., Hutchins L., et al. Antibody responses in melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. Clin Cancer Res 4 (1998) 1117-1124
89. Wagner U., Kohler S., Reinartz S., et al. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. Clin Cancer Res 7 (2001) 1154-1162
90. Herlyn D., Birebent B., Akis N., et al. Colon cancer antigen and anti-idiotype vaccines. Cancer Chemother Biol Response Modif 21 (2003) 287-298
91. Durrant L.G., Parsons T., Moss R., et al. Human anti-idiotypic antibodies can be good immunogens as they target Fc receptors on antigen-presenting cells allowing efficient stimulation of both helper and cytotoxic T-cell responses. Int J Cancer 92 (2001) 414-420
92. Murray J.L., Gillogly M., Kawano K., et al. Fine specificity of high molecular weight-melanoma-associated antigen specific cytotoxic T lymphocytes elicited by anti-idiotypic monoclonal antibodies in patients with melanoma. Cancer Res 64 (2004) 5481-5488
93. H sequence of antiidiotypic antibodies?. Cancer Res 65 (2005) 6002-6005